NEWSAR
Multi-perspective news intelligence
SRCProPublica
LANGEN
LEANCenter-Left
WORDS439
ENT7
FRI · 2026-01-23 · 10:00 GMTBRIEF NSR-2026-0123-9927
News/ProPublica Publishes Unreleased Data on the Origins of Gener…
NSR-2026-0123-9927News Report·EN·Public Health

ProPublica Publishes Unreleased Data on the Origins of Generic Prescription Drugs

ProPublica has released a new dataset, previously unavailable from the FDA, linking generic drugs to their manufacturing factories. This data powers ProPublica's Rx Inspector tool, allowing users to trace generic drugs back to their origin and view FDA inspection records.

Brandon RobertsProPublicaFiled 2026-01-23 · 10:00 GMTLean · Center-LeftRead · 2 min
ProPublica Publishes Unreleased Data on the Origins of Generic Prescription Drugs
ProPublicaFIG 01
Reading time
2min
Word count
439words
Sources cited
1cited
Entities identified
7entities
Quality score
75%
§ 01

Briefing Summary

AI-generated
NEWSAR · AI

ProPublica has released a new dataset, previously unavailable from the FDA, linking generic drugs to their manufacturing factories. This data powers ProPublica's Rx Inspector tool, allowing users to trace generic drugs back to their origin and view FDA inspection records. The dataset was created by linking several FDA datasets and required a lawsuit to obtain some information. Researchers believe this information will significantly aid in evaluating generic drug quality and supply chains, potentially leading to quality-based purchasing decisions by government agencies. While acknowledging potential incompleteness due to outdated information, ProPublica is releasing the data under a Creative Commons license for noncommercial use, aiming to increase transparency in generic drug manufacturing.

Confidence 0.90Sources 1Claims 5Entities 7
§ 02

Article analysis

Model · rule-based
Framing
Public Health
Technology
Tone
Measured
AI-assessed
CalmNeutralAlarmist
Factuality
0.80 / 1.00
Factual
LowHigh
Sources cited
1
Limited
FewMany
§ 03

Key claims

5 extracted
01

ProPublica had to sue the FDA to obtain some of the data.

factualProPublica
Confidence
1.00
02

This bypasses an incredibly time-consuming barrier for people who want to study drugs.

quoteJohn Gray, professor at the Ohio State University
Confidence
1.00
03

The data will allow anyone to connect prescriptions to the facilities they were manufactured in.

factualProPublica
Confidence
1.00
04

The data was created by linking several FDA datasets.

factualProPublica
Confidence
1.00
05

ProPublica published data connecting generic drugs to their manufacturing factories.

factualProPublica
Confidence
1.00
§ 04

Full report

2 min read · 439 words
ProPublica on Friday published never-before-released data connecting generic drugs to the factories that manufactured them. The data powers Rx Inspector, our groundbreaking tool that allows you to find the factories where your generic drugs were made and their Food and Drug Administration inspection track records. The data, which ProPublica created by linking several FDA datasets, has never been made available by the agency before. It will allow anyone to connect prescriptions to the facilities they were manufactured in by linking National Drug Code numbers to FDA Establishment Identifiers of drug manufacturing facilities. Academic researchers said the data would contribute significantly to research evaluating the quality and supply of generic drugs. “This bypasses an incredibly time-consuming barrier for people who want to study drugs and anything to do with manufacturing,” said John Gray, a professor at the Ohio State University. Gray and his team are working to assign generic drugs quality scores based on risk. The goal is to help government purchasers, including the Centers for Medicare & Medicaid Services, buy medications based on quality, not just cost. The data also provides some basic information about each facility, like the country it’s in and the name of the company that registered it. The methods we used to link the FDA’s drug and facility identifiers are complex, and are laid out in our full methodology. To obtain some of the data, ProPublica had to sue the agency. We know that much of what is represented here is likely incomplete. It is possible the FDA’s information is not up-to-date because, for example, one company acquired another or moved its manufacturing to a different location. However, we believe this is an important first step in shedding light on a process that the agency and drugmakers have sought to keep secret from consumers. We are releasing this data under a Creative Commons license, meaning you may use it for noncommercial purposes as long as you attribute ProPublica and link back to Rx Inspector. We will continue to share our areas of interest as the news develops. I cover health and the environment and the agencies that govern them, including the Environmental Protection Agency. Contact me I cover justice and the rule of law, including the Justice Department, U.S. attorneys and the courts. Contact me I report on immigration and labor, and I am based in Chicago. Contact me I cover housing and transportation, including the companies working in those fields and the regulators overseeing them. Contact me to stay in touch. Slide 2 Slide 3 Slide 4 Slide 5 Slide 6 How “Bitcoin Jesus” Avoided Prison, Thanks to One of the “Friends of Trump”
§ 05

Entities

7 identified